fashion -WSS

fashion

author：entertainment 2025-09-27 09:40:03 - browse：94

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： How housing is health care on Long Island

WSS

First Opinion Podcast: Long Covid needs a new approach

IRA could hurt research into orphan drugs for rare diseases

Will the IRA bring competition to the biologics market?

Hospital price transparency does save money, advocate argues

FDA approves updated Covid vaccines

Impact of Dobbs ruling felt at reproductive medicine meeting

explore

fashion

knowledge

New air purifier tech could be key to improving indoor air quality

What to make of Biden’s latest efforts on cancer research

In age of alternative facts, a scholarly course on calling out crap

Food makers to regulators: Ultra

Walensky prepares to leave CDC — and Congress — behind

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Medical leaders decry Supreme Court decision on affirmative action

How climate

Cancer drug shortages should be causing more outrage

White House touts steps to stem shortages of cancer treatments

Wikipedia

Diverse clinical trials: Why aren’t we there yet?

What to make of Biden’s latest efforts on cancer research

2023 STAT Wunderkinds: get to know the winners

How housing is health care on Long Island

How housing is health care on Long Island

Will Ozempic

hotspot

entertainment

entertainment

explore